CARSGEN-B (02171) announces its interim results with a net loss of 75.48 million yuan, a year-on-year decrease of 78.53%.
Kozi Pharmaceutical-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million RMB, a year-on-year increase...
CARSGEN-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million yuan, an increase of 703.8% year-on-year; a gross profit of 29.369 million yuan, an increase of approximately 17.16 times year-on-year; a net loss of 75.483 million yuan, which narrowed by 78.53% year-on-year; and a loss per share of 0.14 yuan.
The announcement stated that the decrease in losses was mainly due to a reduction in research and development expenses, a reduction in administrative expenses, an increase in net foreign exchange gains, and an increase in gross profit.
Related Articles

US Stock Market Move | Lowering the 2025 fiscal year net income outlook, Deere & Company (DE.US) fell by nearly 8%.

US Stock Market Move | Nuclear power sector is trending lower, Oklo Inc (OKLO.US) falls more than 6.9%

US Stock Market Move | Q2 revenue exceeds expectations, Expion360 (XPON.US) soars over 211%
US Stock Market Move | Lowering the 2025 fiscal year net income outlook, Deere & Company (DE.US) fell by nearly 8%.

US Stock Market Move | Nuclear power sector is trending lower, Oklo Inc (OKLO.US) falls more than 6.9%

US Stock Market Move | Q2 revenue exceeds expectations, Expion360 (XPON.US) soars over 211%
